To achieve long term capital appreciation by predominantly investing in equity and equity related instruments of small cap companies. However, there can be no assurance that the investment objective o...
Read MoreThe primary investment objective of the scheme is to provide long-term capital appreciation by investing in units of Wellington Global Innovation Fund or any other similar overseas mutual fund schemes...
Read MoreThe investment objective of the scheme is to achieve return equivalent to Nifty 50 Index by investing in stocks of companies comprising Nifty 50 Index, subject to tracking error. However, there is no ...
Read MoreThe scheme endeavours to provide regular income and capital growth with limited interest rate risk to the investors through investments in a portfolio comprising of debt instruments such as Government...
Read MoreThe investment objective of the schemes is to provide return that closely correspond to the total returns of the securities as represented by the underlying index, subject to tracking error. However, ...
Read MoreTo generate income by investing in a portfolio of Debt and Money Market Instruments such that the Macaulay duration of the portfolio is between 3 years and 4 years. However, there is no assurance or g...
Read MoreTo generate long-term capital appreciation by investing predominately in equity & equity related instruments across market capitalization. However, there can be no assurance or guarantee that the inve...
Read MoreThe investment objective of the scheme is to maximise returns through an active management of a portfolio comprising of debt and money market instruments. However, there can be no assurance that the i...
Read MoreThe scheme seeks to generate income by investing in a portfolio of fixed income securities maturing on or before the duration of the scheme. The scheme does not guarantee/indicate any returns. There c...
Read MoreThe investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject t...
Read More